title: SEOM guidelines for cervical cancer.
abstract: Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-risk human papilloma virus infection. Although screening programs have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in undeveloped countries. Clinical stage is still the most relevant prognostic factor. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. In the setting of recurrent or metastatic CC, for the first time ever, the combination of chemotherapy plus bevacizumab prolongs the overall survival beyond 12 months. Therefore, this regimen is considered by most of the oncologist a new standard of care for metastatic/recurrent CC.
authors.affiliation: Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Ps Vall d'Hebron, 119-129, 08035, Barcelona, Spain. aoaknin@vhio.net.
authors.forename: A
authors.initials: A
authors.lastname: Oaknin
authors.affiliation: Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Rubio
authors.affiliation: Hospital Universitario la Paz, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Redondo
authors.affiliation: Hospital Universitario Marqués de Valdecilla, Santander, Spain.
authors.forename: A
authors.initials: A
authors.lastname: De Juan
authors.affiliation: Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
authors.forename: J F
authors.initials: JF
authors.lastname: Cueva Bañuelos
authors.affiliation: Hospital Durán i Reynals (ICO), Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Gil-Martin
authors.affiliation: Hospital Universitari Arnau de Villanova de Lleida, Lleida, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Ortega
authors.affiliation: Institut Català d'Oncologia, Hospital de Sant Joan Despí-Moisès Broggi, Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Garcia-Arias
authors.affiliation: MD Anderson Cancer Center, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Gonzalez-Martin
authors.affiliation: Hospital Son Llatzer, Palma de Mallorca, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Bover
mesh_terms: D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019468:Disease Management; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D008495:Medical Oncology; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic / Q000592:standards*; D011379:Prognosis; D012955:Societies, Medical; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000628:therapy*
keywords: Cervical cancer; Clinical stage; Human papilloma virus